GSA Capital Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,376
| Closed | -$973K | – | 2239 |
|
|
2025
Q1 | $973K | Buy |
+7,376
| New | +$919K | 0.09% | 360 |
|
|
2024
Q3 | – | Sell |
-3,668
| Closed | -$251K | – | 2095 |
|
|
2024
Q2 | $251K | Buy |
3,668
+315
| +9% | +$21.8K | 0.02% | 1367 |
|
|
2024
Q1 | $232K | Buy |
+3,353
| New | +$230K | 0.02% | 1342 |
|
|
2023
Q4 | – | Sell |
-8,122
| Closed | -$423K | – | 2013 |
|
|
2023
Q3 | $423K | Buy |
8,122
+1,371
| +20% | +$79.9K | 0.04% | 897 |
|
|
2023
Q2 | $427K | Buy |
+6,751
| New | +$421K | 0.04% | 839 |
|
|
2023
Q1 | – | Sell |
-5,490
| Closed | -$291K | – | 2000 |
|
|
2022
Q4 | $291K | Buy |
+5,490
| New | +$275K | 0.04% | 949 |
|
|
2021
Q2 | – | Sell |
-9,216
| Closed | -$313K | – | 1647 |
|
|
2021
Q1 | $313K | Buy |
+9,216
| New | +$320K | 0.05% | 622 |
|
|
2020
Q2 | – | Sell |
-14,043
| Closed | -$216K | – | 1194 |
|
|
2020
Q1 | $216K | Buy |
+14,043
| New | +$305K | 0.05% | 706 |
|
|
2019
Q4 | – | Sell |
-41,823
| Closed | -$312K | – | 1785 |
|
|
2019
Q3 | $312K | Buy |
+41,823
| New | +$401K | 0.04% | 864 |
|
|
2019
Q1 | – | Sell |
-12,449
| Closed | -$142K | – | 1747 |
|
|
2018
Q4 | $142K | Buy |
+12,449
| New | +$201K | 0.02% | 1173 |
|
|
2018
Q3 | – | Sell |
-48,594
| Closed | -$859K | – | 1956 |
|
|
2018
Q2 | $859K | Buy |
48,594
+4,400
| +10% | +$89.3K | 0.04% | 841 |
|
|
2018
Q1 | $930K | Sell |
44,194
-66,906
| -60% | -$1.3M | 0.05% | 707 |
|
|
2017
Q4 | $1.61M | Buy |
+111,100
| New | +$1.72M | 0.1% | 325 |
|
|
2016
Q4 | – | Sell |
-14,100
| Closed | -$215K | – | 2005 |
|
|
2016
Q3 | $215K | Sell |
14,100
-10,968
| -44% | -$443K | 0.01% | 1567 |
|
|
2016
Q2 | $973K | Buy |
25,068
+17,768
| +243% | +$638K | 0.05% | 643 |
|
|
2016
Q1 | $203K | Buy |
+7,300
| New | +$243K | 0.01% | 1488 |
|
Other funds holding ITCI
KIM
HNB